Lewis-Hall Freda C 4
4 · Pyxis Oncology, Inc. · Filed Mar 25, 2026
Research Summary
AI-generated summary of this filing
Pyxis Oncology (PYXS) Director Freda C. Lewis-Hall Receives Award
What Happened
Freda C. Lewis-Hall, a director of Pyxis Oncology (PYXS), received a grant of 45,867 derivative shares recorded as an award on 2026-03-24. The award was reported at a $0.00 acquisition price (typical for option/RSU grants) and has no immediate cash value; it represents compensation rather than an open‑market purchase or sale.
Key Details
- Transaction date: 2026-03-24; Form 4 filed 2026-03-25 (timely filing).
- Transaction type/code: Grant/Award (A); derivative securities granted.
- Shares granted: 45,867 units; acquisition price reported as $0.00.
- Vesting: 100% of the award vests on the first anniversary of the grant, subject to continued service (footnote F1).
- Shares owned after transaction: Not specified in the provided excerpt of the filing.
- No immediate sale or exercise reported; this is a compensation grant, not a cash transaction.
Context: Grants to directors are a common form of compensation and do not necessarily signal buying or selling intent. Because the award vests after one year and wasn't sold, there is no immediate market impact.
Insider Transaction Report
Form 4
Lewis-Hall Freda C
Director
Transactions
- Award
Stock Option (Right to Buy)
[F1]2026-03-24+45,867→ 45,867 totalExercise: $1.36Exp: 2036-03-24→ Common Stock (45,867 underlying)
Footnotes (1)
- [F1]The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date.
Signature
/s/ Jitendra Wadhane, Attorney-in-Fact for Freda Lewis-Hall|2026-03-25